Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PA
Passage Bio, Inc. Common Stock
PASG
Volume
16.69K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PA
PASG
PA
Passage Bio, Inc. Common Stock
PASG
News
·
Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034
Mkt Cap
$11.6M
Volume
16.69K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034
The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.
GlobeNewswire Inc. · Oct 17, 2025
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies
The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.
GlobeNewswire Inc. · Mar 4, 2025
Passage Bio to Participate in Upcoming Investor Conferences
Passage Bio, a clinical-stage genetic medicines company, announced that it will participate in upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Global Biopharma Conference.
GlobeNewswire Inc. · Feb 26, 2025
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Passage Bio, a clinical-stage genetic medicines company, announced that its president and CEO will present at the Guggenheim Securities Healthcare Innovation Conference on November 13, 2024. The company is focused on developing one-time therapies for neurodegenerative diseases, with its lead product candidate PBFT02 targeting frontotemporal dementia.
GlobeNewswire Inc. · Nov 6, 2024
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
Passage Bio, a clinical-stage genetic medicines company, announced that its president and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024.
GlobeNewswire Inc. · Aug 30, 2024
Passage Bio Announces Positive Feedback from FDA on - GlobeNewswire
Passage Bio received positive feedback from the FDA to expand its upliFT-D trial of PBFT02 to include FTD-C9orf72 patients, a move that could address a significant unmet need in this underserved patient community.
GlobeNewswire Inc. · Jul 16, 2024
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks Investment Research · Jun 18, 2024
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 4:00 p.m. ET.
GlobeNewswire Inc. · Jun 5, 2024
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research · May 16, 2024
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, May 14, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2024 and provided recent business highlights.
GlobeNewswire Inc. · May 14, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PA
PASG
Passage Bio, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
PASG
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PASG yet.
Related Tickers
Earnings